Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2NIH 1NETWORK 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 4Other 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 5Prostatic Neoplasms 4Breast Neoplasms 4Oropharyngeal Neoplasms 3Neoplasms 3Endometrial Neoplasms 3Stomach Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Diseases 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pleuropulmonary blastoma 1Pathologic Complete Response 1Paranasal Sinus Neoplasms 1Pancreatitis, Chronic 1Obesity 1Neurocognitive Disorders 1Neuroblastoma 1Neoplasm Metastasis 1

Interventions

Fulvestrant 62Paclitaxel 52Letrozole 51pembrolizumab 39Trastuzumab 38ribociclib 37Capecitabine 36Specimen Handling 34palbociclib 33Carboplatin 33Anastrozole 33exemestane 30Tamoxifen 30abemaciclib 29Cyclophosphamide 26pertuzumab 25Magnetic Resonance Spectroscopy 25trastuzumab deruxtecan 24Surveys and Questionnaires 20Blood Specimen Collection 20Radiotherapy 19olaparib 17Biopsy 16130-nm albumin-bound paclitaxel 16Standard of Care 15Docetaxel 15eribulin 14Methods 14Early Intervention, Educational 14inavolisib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Breast Neoplasms × Observation × 90 days × Clear all
NCT02954874 2026-05-15

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,155 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Canadian Cancer Trials Group

Phase 2 Recruiting
484 enrolled
Breast

Breast Neoplasms

NCT03503799 2026-04-13

RESCUE

North Eastern German Society of Gynaecological Oncology

Active not recruiting
1,191 enrolled
Breast

Breast Neoplasms

NCT07447440 2026-03-11

RESOLBE

Clinica Universidad de Navarra, Universidad de Navarra

Recruiting
60 enrolled
BreastOther

Breast Neoplasms, Neoplasms, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡